IBI351+AK112
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
KRAS G12C Lung Cancer
Conditions
KRAS G12C Lung Cancer
Trial Timeline
Apr 30, 2025 → Mar 30, 2028
NCT ID
NCT06936644About IBI351+AK112
IBI351+AK112 is a phase 2 stage product being developed by Innovent Biologics for KRAS G12C Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06936644. Target conditions include KRAS G12C Lung Cancer.
What happened to similar drugs?
0 of 2 similar drugs in KRAS G12C Lung Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06936644 | Phase 2 | Recruiting |
Competing Products
20 competing products in KRAS G12C Lung Cancer